Introduction
In our previous studies we found that the combination of 13-cis retinoic acid (13cRA) and lovastatin significantly reduced tumour growth in a mouse phaeochromocytoma allograft model, with the lowest microvessel density in the combination-treated tumours Nölting et al., Endocrinology, 2014 Jul). We have now investigated the effect of 13cRA plus lovastatin on neuroendocrine (BON1, H727) and nonendocrine tumour (HepG2, Huh7) cell viability and signalling pathways (EGFR, AKT, ERK, p70S6K) to elucidate the underlying mechanism of action. 
Methods
Cell viability was assessed with the MTS assay, the effect on signalling pathways by Western blotting. For cell viability data, the multiplecomparison Kruskal-Wallis-Test was used, followed by pairwise comparisons with the Mann-Whitney-Test. Interaction effects were analysed with LinearMixed-Effects-Models. Statistical significance was defined at p≤0.05. 
Results
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Fig.2:
The combination of 10μM lovastatin plus 7.5μM 13cRA shows synergistic inhibition of BON1 cell viability (p≤0.05) (@) Fig.3 : In H727 cells, 10μM lovastatin plus 3.75μM or 7.5μM 13cRA significantly more strongly reduces cell viability than each drug separately (p≤0.05) (*), but this effect is not synergistic.
Conclusion
•Synergistic effect of 13cRA plus lovastatin in BON1 cells at clinically relevant doses, associated with enhanced EGFR inhibition
•Consistent with our in vivo data in a phaeochromocytoma allograft model showing slowest tumour growth and lowest microvessel density after 13cRA/lovastatin-treatment •Potentially novel effective drug combination 
